Figure 7
From: Tumor resident memory CD8 T cells and concomitant tumor immunity develop independently of CD4 help
Concomitant tumor immunity is dependent on CD40L. (a)(i) Mice were implanted with a primary sc. PK5L1940 tumor on d0 and a secondary sc. tumor on the opposite flank at d0 or d7 (with and without CD8 depletion). Graphs show the size of the primary (1°) and secondary tumor (2°) at d14. (ii) Mice bearing a primary sc. PK5L1940 tumor were injected with a secondary tumor sc. on d7 or d21. The number of SIY-specific CD8 T cells were determined 0, 7 and 14d following secondary tumor implantation. (b) Mice were implanted with a primary sc. PK5L1940 tumor or no treatment at d0, and a secondary sc. tumor on d7. Groups of mice also received anti-CD40L on d0, 1, and 2, anti-CD4 on d-1, or anti-CD8 on d6. Additional groups received FTY-720 IP on days 6–11. Graphs show the size of the (i) primary (1°) and (ii) secondary tumor (2°) on d21. (iii) Proportion of mice secondary tumor free on d21. (c) Mice were implanted with a primary sc. PK5L1940 tumor or no treatment at d0 or were vaccinated with Lm-SIY or Lm-Ova IV on d0. Mice received a secondary sc. tumor on d7. Peripheral blood was analyzed for (i) SIY-specific T cells or (ii) ova-specific T cells on d7. (iii) Size of secondary tumors on d21. (iv) proportion of mice tumor-free on d21. Key: NS = not significant; * = p < 0.05; ** = p < 0.01; *** = p < 0.001; **** = p < 0.0001. Results are the combination of 4–5 experiments.
